ArchiveChronic obstructive pulmonary disease is a heterogeneous lung condition with multiple complications and requires multidimensional evaluation. The international classification of functioning, disability and health (ICF) constructs a bio-psycho-social model, including physical functions, body structure, activities and participation and environmental factors. Based on the ICF framework, this paper mainly applied the literature research method to analyze the core set of obstructive pulmonary disease (OPD), which means “why this category can be included in the ICF-OPD core sets”, and analyzed the clinical application of this set.
Gut-lung axis is an important endocrine regulatory axis in the human body which can influence and regulate the progression of chronic obstructive pulmonary disease (COPD). The gut-lung axis changes in COPD patients, which are reflected in the changes of lung microbes, gut microbes, and gut-lung axis immune modulating network. In gut-lung axis, components of gut microbes, crosstalk of microbes in gut and lung, microbe metabolites of gut microbes can all result in the exacerbation of COPD. However, clinical evidence indicates that the diversity of lung microbes cannot completely cause exacerbation of COPD, which may be related to the poor stability of lung microbes in COPD patients. Mechanisms of gut-lung axis on COPD progression include: the bacterial metabolite pathway and the immunity pathway, which further includes innate and adaptive immunity modulation and inflammatory agent cascades. In addition, there are still mucous immunity modulation and cytology modulation.
Chronic obstructive pulmonary disease (COPD) is a common clinical chronic airway disease. Although the existing treatment strategies can effectively control and relieve the symptoms of the disease, the disease is difficult to recover. New approaches are required to prevent the progress of the disease and reverse lung function deterioration. With the development of the gut-lung axis research in recent years, the study of prevention and treatment of COPD through intervention of the gut microbiome is gradually advancing. This article reviewed the research progress on regulating gut microbiome to treat COPD, aiming to explore new ideas for COPD prevention and provide direction for further clinical research and application of therapies based on the lung-gut axis.
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. Inspiratory muscle training (IMT), as a common method of pulmonary rehabilitation in patients with COPD, can improve symptoms and quality of life. This article reviewed the relevant studies on IMT in patients with COPD at different disease stages, and expounded the relevant mechanism, implementation method and clinical application value, in order to provide reference for further IMT in patients with COPD.
To investigate the effect of saxagliptin on podocyte injury induced by high glucose by regulating the microRNA (miR)-23b-3p/early growth response factor (EGR)1 axis.
Human podocytes were divided into control group, high glucose group, high glucose+saxagliptin group, high glucose+saxagliptin+anti-miR-control group and high glucose+saxagliptin+anti-miR-23b-3p group. The expression of miR-23b-3p, EGR1 messenger RNA (mRNA), proliferation, apoptosis, reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), interleukin (IL)-1β, IL-6, desmin, split pore membrane proteins (Podocin, Nephrin), B cell lymphoma-2 related X protein (Bax), Caspase-3 and EGR1 protein were detected, the targeting relationship between miR-23b-3p and EGR1 was verified.
Compared with control group, the expression level of miR-23b-3p, proliferation rate, SOD, Podocin and Nephrin in high glucose group were obviously decreased, while the expression of EGR1 mRNA and protein, apoptosis rate, IL-1β, IL-6, MDA, ROS, Caspase-3, Bax and desmin were increased (P<0.05). Compared with high glucose group, the expression level of miR-23b-3p, proliferation rate, SOD, Podocin and Nephrin in high glucose+saxagliptin group were obviously increased, while the expression of EGR1 mRNA and protein, apoptosis rate, IL-1β, IL-6, MDA, ROS, Caspase-3, Bax and desmin were decreased (P<0.05). Down-regulation of miR-23b-3p could attenuate the improvement of saxagliptin on podocyte injury (P<0.05). MiR-23b-3p negatively regulated the expression of EGR1.
Saxagliptin may reduce high glucose-induced apoptosis and injury of podocytes by up-regulating miR-23b-3p and negatively regulating EGR1.
To investigate the association between plasma advanced glycation end products (AGEs) and carotid-femoral pulse wave velocity (cf-PWV) and urine albumin/creatinine ratio (ACR) in adults with hypertension.
The study subjects were patients who went to Ruijin hospital, Shanghai Jiao Tong university school of medicine for ambulatory blood pressure monitoring. The general condition and medical history of the hypertensive patients were collected through questionnaire survey, the brachial artery blood pressure was measured by Omron upper arm sphygmomanometer (HEM-7051), fasting blood was collected to determine biochemical indexes, including total cholesterol, triacylglycerol, and fasting blood glucose, and plasma AGEs concentration was measured by enzyme-linked immunosorbent assay. Urine ACR and cf-PWV measured by SpygmoCor software were used as indicators of target organ damage in hypertension.
The mean age of the 175 subjects was (51.23±11.38) years old, of which 78 were male (44.57%), accounting for 44.57%. The plasma AGEs level was higher in males compared to females [(7.80±6.37)μg/ml vs (4.41±3.62)μg/ml, P<0.001]. In terms of target organ damage, urinary ACR level in males was lower compared to females [(1.18±0.70) mg/mmol vs (2.10±2.17) mg/mmol, P<0.001]. There was no significant difference in cf-PWV (P=0.27). Before adjusting for related risk factors, plasma AGEs concentrations were positively correlated with fasting glucose (r=0.163, P=0.030), blood creatinine (r=0.219, P=0.003), and urinary ACR (r=0.150, P=0.046), and negatively correlated with high density lipoprotein cholesterol (r=-0.206, P=0.006). There was no significant correlation with cf-PWV (r=0.101, P=0.182). Multivariate stepwise linear regression analysis revealed that after adjustment for relevant risk factors, urinary ACR increased by 2.2% for each 1 μg/ml increase in plasma AGEs (P=0.023). There was no significant change in cf-PWVP (P=0.738).
Plasma AGEs concentration is an independent risk factor for the urinary ACR.
To explore the possible relationships between hypertension, proteinuria, gender, body mass, height, and other factors in the adolescent population by analyzing data on blood pressure, height, body mass, and urinary protein in 1 748 adolescents aged 11 to 17.
SPSS22.0 was used as the statistical analysis software. The statistical methods involved χ2 test, t-test, one-way analysis of variance, binary and multiple logistic regression.
A total of 1 748 adolescents aged between 11 and 17 from four middle schools in Shanghai were analyzed. The analysis found that the risk of hypertension in children aged 11 - 13 was 1.69 times higher than that of adolescents aged 14 - 17, and the incidence of grade 2 hypertension was 2.13 times higher. The risk of normal high blood pressure in women was 1.54 times higher than that in men, and the incidence of abnormal blood pressure in lean and normal individuals was significantly lower than that in obese individuals. The positive rate of urinary albumin/creatinine ratio (UACR) was affected by gender, age and blood pressure. The risk of women was 3.27 times higher than that of men, and the risk of children was 1.63 times higher than that of adolescents. Grade 2 hypertension significantly increased UACR positivity rate, but other blood pressure levels did not show significant differences.
There is a certain correlation between adolescent blood pressure levels and age, body mass index grading and gender. The positive rate of UACR is related to gender, age group and abnormal blood pressure, but only grade 2 hypertension increases the risk of UACR positivity.
To explore the effect of tirofiban combined with sodium nitroprusside in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).
The clinical data of 97 patients with AMI who underwent PCI in our hospital from June 2019 to June 2022 were retrospectively analyzed, and the patients were divided into tirofiban group (n=48, tirofiban) and combination group (n=49, tirofiban combined with sodium nitroprusside) according to different medication regiments during PCI. Immediate postoperative blood flow improvement, ST segment regression at 2 h after surgery, serum cardiac troponin (cTn) I level before and after surgery, indexes of cardiac function before and after surgery [left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)] and the incidence of major adverse cardiac event (MACE) within 3 months after surgery were compared between the two groups.
The blood flow improvement rate and ST segment regression rate in the combination group were 97.96% and 95.92%, respectively, which were obviously higher than those in the tirofiban group (87.50% and 83.33%)(P<0.05). On the 3rd day after operation, the level of serum cTnI in the two groups were lower than those before operation (P<0.05), and the combination group was obviously lower than the tirofiban group (P<0.05). One month after operation, the LVEDD in both groups were lower than those before operation (P<0.05), and the LVEF were higher than those before operation (P<0.05), and the above cardiac function indexes in the combination group were obviously better than those in the tirofiban group (P<0.05). The incidence of MACE in the combination group was obviously lower (4.08%) than that in the tirofiban group (18.75%)(P<0.05).
Combined application of tirofiban and sodium nitroprusside during PCI in patients with AMI can effectively promote ST segment regression and coronary blood flow recovery, obviously improve cardiac function, and significantly reduce serum cTnI level and the risk of MACE.
To analyze retrospectively the effects of advanced age and diabetes mellitus (DM) on nucleic acid outcome of 2019 novel coronavirus (2019-nCoV).
A total of 748 cases of 2019-nCoV asymptomatic infection or mild patients who were positive for nucleic acid screening were collected from Fuchang road shelter, Baoshan district, Shanghai in April 2022. The effects of age and DM on the number of days of negative nucleic acid transformation were analyzed.
The number of days for nucleic acid to turn negative was (6.96±3.15) d for patients <40 years old (269 cases), (6.92±3.24)d for patients 40 – 50 years old (173 cases), (7.33±3.22)d for patients 50 - 60 years old (167 cases), (7.48±2.88)d for patients 60 - 70 years old (131 cases), (8.25±5.92)d for patients over 70 years old (8 cases). The difference was not statistically significant (P>0.05). The number of days for nucleic acid to turn negative was (7.57±3.29)d for patients with DM (113 cases), (7.06±3.16)d for patients without DM (635 cases), with no statistical significance (P>0.05).
There is no significant correlation between age, DM history, and the number of days of negative nucleic acid transformation in 2019-nCoV asymptomatic infected patients or mild patients, simply considering the age or combined DM can not predict the time of negative nucleic acid transformation.
To explore the effects of roxadustat combined with high-flux hemodialysis (HFHD) on calcium and phosphorus metabolism and total iron binding capacity (TIBC) in patients with chronic kidney disease (CKD).
A total of 80 CKD patients diagnosed with HFHD in the department of nephrology, Harbin the first hospital from January 2021 to December 2022 were selected and divided into control group and observation group according to random number table method, with 40 cases in each group. The control group received recombinant human erythropoietin combined with HFHD, and the observation group received roxadustat combined with HFHD. Efficacy, anemia related factors [hematocrit (HCT), hemoglobin (Hb)], iron metabolism related factors [TIBC, transferrin (TRF), TRF saturation (TSAT)], calcium and phosphorus metabolism related factors [serum calcium, serum phosphorus, parathyroid hormone (PTH)], serum inflammatory factors [tumor necrosis factor (TNF)-α, interleukin (IL)-6, C-reactive protein (CRP)], and the incidence of adverse reactions were compared between the two groups.
The total effective rate of observation group was higher than that of control group (92.50% vs 75.00%, P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (7.50% vs 20.00%, P<0.05). The levels of Hb, HCT, TIBC, TRF and TSTA in observation group were higher than before treatment (P<0.05), and the levels in observation group were higher than those in control group (P<0.05). The levels of serum calcium, serum phosphorus, PTH, TNF-α, IL-6 and CRP in observation group were all decreased (P<0.05), and the levels in observation group were lower than those in control group (P<0.05).
Roxadustat combined with HFHD can significantly improve iron metabolism, calcium and phosphorus metabolism, anemia and inflammation in patients with CKD, with good safety.
To compare the efficacy and safety of azithromycin and minocycline hydrochloride in the treatment of female Mycoplasma infection in genital tract.
A retrospectively study was conducted on Mycoplasma culture and drug sensitivity of patients treated in our center from 2019 to 2021. One hundred and thirty-six patients with Mycoplasma infection in genital tract in our center in April to December 2021 were selected and divided into control groups and observation group, the control groups were given azithromycin for 5 or 7 days, and the observation group was given minocycline hydrochloride for 10 days, respectively, and then compared the effectiveness and safety indicators.
The observation group was better than the two control groups in mean therapeutic effect, incidence of drug resistance and pathogen clearance rate (P<0.05). There was no statistically significant difference in all aspects between control group 1 and control group 2 (P>0.05).
Minocycline hydrochloride has better efficacy, lower drug resistance rate and higher safety in treating genital Mycoplasma infection. There was no significant difference between the 5-day and 7-day methods of azithromycin in all respects.
To compare the efficacy of mesalazine and salazepyridine in the treatment of children with mild to moderate ulcerative colitis (UC).
A total of 80 children with mild to moderate UC admitted to our hospital from April 2021 to February 2023 were selected and divided into control group and observation group by simple sorting, with 40 cases in each group. The control group received salazepyridine treatment, and the observation group received mesalazine treatment, the course of treatment was 2 months. The clinical efficacy and the changes of intestinal flora, serum D-lactic acid (LAC), perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA), the levels of diamine oxidase (DAO), endotoxins (ET), interleukin (IL)-1β, IL-6 and IL-23 before and after treatment were compared between the two groups, and adverse reactions during treatment and disease recurrence at 12 months of follow-up were recorded.
After treatment, the clinical effect of observation group was better than that of control group (P<0.05). Serum levels of D-LAC, P-ANCA, DAO, ET, IL-1β, IL-6 and IL-23 in observation group were lower than those in control group (P<0.05). Enterococcus, Saccharomycetes and Enterobacter were lower than those in control group (P<0.05), Lactobacillus, Bifidobacterium and Bacteroides were higher than those in control group (P<0.05). The number of adverse reactions in control group was higher than that in observation group, but there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). After 12 months of follow-up, there was no significant difference in UC recurrence between the two groups (P>0.05).
Both mesalazine and salazepyridine can be used in the treatment of children with mild to moderate UC. Compared with salazepyridine, mesalazine has more advantages in efficacy, reducing serum D-LAC and p-ANCA expression, regulating intestinal flora, inhibiting inflammatory response, and improving intestinal barrier function, with better safety.
To explore the effects of Nao An dropping pill combined with butylphthalein on serum β2-microglobulin (MG) and homocysteine (HCY) and recombinant S100 calcium binding protein β (S100β) levels in the central nervous system in patients with acute ischemic stroke (AIS).
199 AIS patients treated in our hospital from January 2020 to June 2022 were selected and divided into experimental group (butylphthalein+Nao An dropping pill, n=100) and control group (butylphthalein, n=99) by random number table method. The clinical efficacy, serum β2-MG, HCY, S100β, national institute of health stroke scale (NIHSS), mini mental status examination (MMSE) and the incidence of complications were compared between the two groups.
After treatment, the total effective rate of experimental group was higher than that of control group (92.00% vs 74.75%), and the difference was statistically significant (P<0.05). Serum β2-MG, HCY and S100β levels in the two groups were lower than before, and experimental group was lower than control group (P<0.05). NHISS scores in both groups were lower than before, and the experimental group was lower than the control group (P<0.05). MMSE score levels were higher than before, and experimental group was higher than control group (P<0.05). The incidence of adverse reactions in experimental group was lower than that in control group (3.00% vs 5.05%), but the difference was not statistically significant (P>0.05).
Nao An dropping pill combined with butylphthalein has a good effect on AIS, which may be related to the improvement of β2-MG, HCY and S100β levels.
Target drugs for pulmonary arterial hypertension (PAH) have alleviated the clinical symptoms and improved exercise tolerance, accordingly significantly improved the prognosis of PAH patients since launched into the market. Presently most targeted drugs research focused on PAH. For pulmonary hypertension associated with lung diseases and/or hypoxia, and pulmonary hypertension associated with pulmonary artery obstructions, the clinical treatment evidence of PAH targeted drugs has increased in recent years. Based on this, this article reviewed the progress of PAH targeted drugs on different types of pulmonary hypertension, and provided reference for clinical rational drug use.
Mongolian medicine Sugmuler-3 decoction is a traditional preparation commonly used in Mongolian medicine to treat insomnia. It has been used in clinic for many years, with definite curative effect and few adverse reactions, and is favored by patients. In this paper, chemical composition, pharmacological activity, quality control and clinical application of Sugemuler-3 decoction were summarized to provide reference for its further research and application in the future.
In recent years, the research and development (R&D) of gene therapy has been increasingly highlighted, particularly in the field of rare diseases. As of August 4, 2023, a total of 10 rare disease gene therapy drugs have been approved for market in the world. There are 170 drugs in clinical and registration phases overseas, 46 drugs in clinical stages in China, and most of which are in early clinical phases. The indications covered by gene therapy drugs developed overseas are broader, while drugs developed locally in China have relatively concentrated indications. Biotech companies are the primary R&D enterprises of gene therapy for rare diseases, and many large MNC companies have entered this field through collaboration and acquisition. Currently, there are almost no large and medium-sized companies in China engaged in the R&D of gene therapy for rare diseases. With the development of innovative gene therapy-related technologies and support from relevant regulations, gene therapy will attract increasing attention from Chinese companies in the future. This article analyzed the gene therapy drugs that were currently approved and under development in the world for treating rare diseases to understand the R&D status of gene therapy for rare diseases drugs in China and abroad.
By analyzing the utilization of anesthesia drugs in sample hospitals in Shanghai in recent three years, the development status and trend of anesthesia drugs was understood, so as to provide reference for clinical rational drug use.
The clinical sampling data of anesthesia drugs in sample hospitals in Shanghai from 2020 to 2022 were collected from the Hospital Prescription Analysis System database of China National Pharmaceutical Industry Information Center to analyze the clinical application of anesthesia drugs in the recent three years.
Under the influence of centralized drug quantity purchase policy, the price of some non-controlled anesthetics decreased, and the overall anesthesia drugs showed a downward trend, especially in outpatient and emergency departments. The compound growth rate of outpatient and emergency prescriptions in tertiary hospitals and secondary hospitals was -11.89% and -26.63%, respectively. The average cost of medical institutions at all levels decreased to different degrees, and the average compound growth rate of outpatient and emergency costs in tertiary hospitals and secondary hospitals was -20.57% and -27.16%, respectively. Due to the controllability, accuracy and convenience of inhalation anesthetics, the clinical application is expanded and the growth is good. In recent years, the increase of approved drugs and the advent of domestic class I of innovative drugs and product update iteration have increased the clinical selectivity of anesthetics. Clinical use of drugs alone is still the majority and the number of prescriptions accounted for 80.65%.
The anesthetics control measures of Shanghai sample hospitals are active and effective, but the multi-drug combination scheme still needs to be actively explored.
The listing and commercial success of belumosudil, the Rho associated coiled-coil-containing protein kinase (ROCK)2 inhibitor, means that ROCK2 target has withstood both clinical trials and test of market. Such targets that have been clinically tested and have good market prospects are usually recognized and followed by domestic innovative drug companies. However, there are few domestic innovative researchers of ROCK2 targets. This paper analyzed this abnormal phenomenon, it was believed that the incomplete patent layout of belumosudil in China was an important reason for the lack of follow-up by domestic innovative pharmaceutical companies. It was also concluded that the patent layout played an important role in the research and development of innovative drugs.